MovDisordV3, Main, Exploration, bibRecord, 001589

Levodopa is not a useful treatment for Lesch‐Nyhan disease

Identifieur interne : 001589 ( Main/Exploration ); précédent : 001588; suivant : 001590

Levodopa is not a useful treatment for Lesch‐Nyhan disease

Auteurs : Jasper E. Visser [Pays-Bas] ; David J. Schretlen [États-Unis] ; Bastiaan R. Bloem [Pays-Bas] ; Hyder A. Jinnah [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 2011-03.

RBID : ISTEX:466B646823D61BEDDFA107E2CBFE202706039751

Descripteurs français

Pascal (Inist)
- Automutilation, Comportement, Dyskinésie, Dystonie, Lévodopa, Pathologie du système nerveux, Traitement.

English descriptors

KwdEn :
- Adult, Antiparkinson Agents (contraindications), Behavior, Child, Child, Preschool, Dyskinesia, Dystonia, Female, Humans, Lesch-Nyhan Syndrome (drug therapy), Lesch‐Nyhan disease, Levodopa, Levodopa (contraindications), Male, Nervous system diseases, Self injury, Treatment, Treatment Outcome, dyskinesias, dystonia, levodopa, self‐injurious behavior, treatment.
MESH :
- chemical , contraindications : Antiparkinson Agents, Levodopa.
- drug therapy : Lesch-Nyhan Syndrome.
- Adult, Child, Child, Preschool, Female, Humans, Male, Treatment Outcome.

Abstract

Lesch‐Nyhan disease (LND) is characterized by dystonia, cognitive abnormalities, and self‐injurious behavior. No effective therapies are available. LND is associated with a presynaptic dopaminergic deficit, but the reported effects of dopamine replacement therapy are conflicting. The current prospective open‐label study assesses the effects of levodopa on both neurological and behavioral features of LND. All 6 study participants discontinued levodopa early, due to lack of effect and sometimes worsening of motor function. The results provide important clues for pathophysiological mechanisms and suggestions for future treatment options. © 2011 Movement Disorder Society

Url:

DOI: 10.1002/mds.23478

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa is not a useful treatment for Lesch‐Nyhan disease</title>
<author><name sortKey="Visser, Jasper E" sort="Visser, Jasper E" uniqKey="Visser J" first="Jasper E." last="Visser">Jasper E. Visser</name>
</author>
<author><name sortKey="Schretlen, David J" sort="Schretlen, David J" uniqKey="Schretlen D" first="David J." last="Schretlen">David J. Schretlen</name>
</author>
<author><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R." last="Bloem">Bastiaan R. Bloem</name>
</author>
<author><name sortKey="Jinnah, Hyder A" sort="Jinnah, Hyder A" uniqKey="Jinnah H" first="Hyder A." last="Jinnah">Hyder A. Jinnah</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:466B646823D61BEDDFA107E2CBFE202706039751</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23478</idno>
<idno type="url">https://api.istex.fr/document/466B646823D61BEDDFA107E2CBFE202706039751/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001705</idno>
<idno type="wicri:Area/Istex/Curation">001705</idno>
<idno type="wicri:Area/Istex/Checkpoint">000321</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Visser J:levodopa:is:not</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3523804</idno>
<idno type="RBID">PMC:3523804</idno>
<idno type="wicri:Area/Pmc/Corpus">000238</idno>
<idno type="wicri:Area/Pmc/Curation">000238</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000259</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001265</idno>
<idno type="wicri:Area/PubMed/Curation">001265</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001271</idno>
<idno type="wicri:Area/Ncbi/Merge">003162</idno>
<idno type="wicri:Area/Ncbi/Curation">003162</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003162</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Visser J:levodopa:is:not</idno>
<idno type="wicri:Area/Main/Merge">001642</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0228399</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000631</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002687</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000542</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Visser J:levodopa:is:not</idno>
<idno type="wicri:Area/Main/Merge">001B32</idno>
<idno type="wicri:Area/Main/Curation">001589</idno>
<idno type="wicri:Area/Main/Exploration">001589</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Levodopa is not a useful treatment for Lesch‐Nyhan disease</title>
<author><name sortKey="Visser, Jasper E" sort="Visser, Jasper E" uniqKey="Visser J" first="Jasper E." last="Visser">Jasper E. Visser</name>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Centre, Nijmegen</wicri:regionArea>
<placeName><settlement type="city">Nimègue</settlement>
<region type="province" nuts="2">Gueldre</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Neurology, Amphia Hospital, Breda</wicri:regionArea>
<wicri:noRegion>Breda</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schretlen, David J" sort="Schretlen, David J" uniqKey="Schretlen D" first="David J." last="Schretlen">David J. Schretlen</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R." last="Bloem">Bastiaan R. Bloem</name>
<affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Neurology, Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen Medical Centre, Nijmegen</wicri:regionArea>
<placeName><settlement type="city">Nimègue</settlement>
<region type="province" nuts="2">Gueldre</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Jinnah, Hyder A" sort="Jinnah, Hyder A" uniqKey="Jinnah H" first="Hyder A." last="Jinnah">Hyder A. Jinnah</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology and Human Genetics, Emory University School of Medicine, Atlanta, Georgia</wicri:regionArea>
<placeName><region type="state">Géorgie (États-Unis)</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-03">2011-03</date>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="746">746</biblScope>
<biblScope unit="page" to="749">749</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">466B646823D61BEDDFA107E2CBFE202706039751</idno>
<idno type="DOI">10.1002/mds.23478</idno>
<idno type="ArticleID">MDS23478</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antiparkinson Agents (contraindications)</term>
<term>Behavior</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Dyskinesia</term>
<term>Dystonia</term>
<term>Female</term>
<term>Humans</term>
<term>Lesch-Nyhan Syndrome (drug therapy)</term>
<term>Lesch‐Nyhan disease</term>
<term>Levodopa</term>
<term>Levodopa (contraindications)</term>
<term>Male</term>
<term>Nervous system diseases</term>
<term>Self injury</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>dyskinesias</term>
<term>dystonia</term>
<term>levodopa</term>
<term>self‐injurious behavior</term>
<term>treatment</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="contraindications" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lesch-Nyhan Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Automutilation</term>
<term>Comportement</term>
<term>Dyskinésie</term>
<term>Dystonie</term>
<term>Lévodopa</term>
<term>Pathologie du   système nerveux</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lesch‐Nyhan disease (LND) is characterized by dystonia, cognitive abnormalities, and self‐injurious behavior. No effective therapies are available. LND is associated with a presynaptic dopaminergic deficit, but the reported effects of dopamine replacement therapy are conflicting. The current prospective open‐label study assesses the effects of levodopa on both neurological and behavioral features of LND. All 6 study participants discontinued levodopa early, due to lack of effect and sometimes worsening of motor function. The results provide important clues for pathophysiological mechanisms and suggestions for future treatment options. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Pays-Bas</li>
<li>États-Unis</li>
</country>
<region><li>Gueldre</li>
<li>Géorgie (États-Unis)</li>
<li>Maryland</li>
</region>
<settlement><li>Nimègue</li>
</settlement>
</list>
<tree><country name="Pays-Bas"><region name="Gueldre"><name sortKey="Visser, Jasper E" sort="Visser, Jasper E" uniqKey="Visser J" first="Jasper E." last="Visser">Jasper E. Visser</name>
</region>
<name sortKey="Bloem, Bastiaan R" sort="Bloem, Bastiaan R" uniqKey="Bloem B" first="Bastiaan R." last="Bloem">Bastiaan R. Bloem</name>
<name sortKey="Visser, Jasper E" sort="Visser, Jasper E" uniqKey="Visser J" first="Jasper E." last="Visser">Jasper E. Visser</name>
</country>
<country name="États-Unis"><region name="Maryland"><name sortKey="Schretlen, David J" sort="Schretlen, David J" uniqKey="Schretlen D" first="David J." last="Schretlen">David J. Schretlen</name>
</region>
<name sortKey="Jinnah, Hyder A" sort="Jinnah, Hyder A" uniqKey="Jinnah H" first="Hyder A." last="Jinnah">Hyder A. Jinnah</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001589 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001589 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:466B646823D61BEDDFA107E2CBFE202706039751
   |texte=   Levodopa is not a useful treatment for Lesch‐Nyhan disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Levodopa is not a useful treatment for Lesch‐Nyhan disease

Levodopa is not a useful treatment for Lesch‐Nyhan disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.